News und Analysen
A Once-in-a-Generation Investment Opportunity: 1 Artificial Intelligence (AI) Growth Stock to Buy Now and Hold Forever
Microsoft co-founder Bill Gates says artificial intelligence (AI) is the most revolutionary technology he has seen in decades. He formed that opinion after watching ChatGPT ace a college-level
Is EV Company QuantumScape a Buy While It's Down?
There was plenty of euphoric excitement over all things electric vehicle (EV) a few years ago. Every investor wanted to find the next Tesla. One way to play that was to invest in a company that
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
If you're looking for a stock that has the potential to grow your investment to $1 million, a good move may be to invest in a strong business that's in a fast-growing industry. Gene therapy is an
You Won't Believe My Apple Stock Prediction for 2024
Fool.com contributor Parkev Tatevosian evaluates Apple (NASDAQ: AAPL) across several financial metrics, including valuation, to determine if the stock is a buy for 2024.
*Stock prices used were the
Why NetEase, Huya, and Gaotu Techedu Stocks All Dropped Today
As the trading week winds down on Friday and heads into the holidays, there's big trouble brewing in China's big tech sector. Shares of online gaming company NetEase (NASDAQ: NTES) crashed 15%
Will Theme Park Stocks Bounce Back in 2024?
There was a lot of love for theme parks this year from thrill-seeking fans of these massive outdoor havens of escapism. Wall Street hasn't been as kind. Walt Disney (NYSE: DIS) -- operator of the
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
Could the rare-disease-focused biotech Sarepta Therapeutics (NASDAQ: SRPT) one day become a towering, innovative, and profitable growth business, as biopharma Vertex Pharmaceuticals (NASDAQ: VRTX)
Where Will Regeneron Pharmaceuticals Be in 1 Year?
Regeneron Pharmaceuticals (NASDAQ: REGN) is a growing biotech company that generates a ton of free cash flow. Over the years, it has obtained approval or authorization for 12 medicines. Its strong
Dutch Bros Stock Beat Starbucks in 2023. Is It a Buy Now?
Neither stock was a big winner this year, but Wall Street still had a clear favorite when it comes to Starbucks (NASDAQ: SBUX) and Dutch Bros (NYSE: BROS). The coffee titan lost 2% of its value
A Bull Market Is Coming: 2 Growth Stocks Down 61% and 32% to Buy Right Now
With the S&P 500 now down just 1% from its record level, the benchmark index could be on the verge of reaching a new peak and ushering in the next sustained bull market.
But while the index has
Why PayPal Could Explode Higher in 2024
PayPal (NASDAQ: PYPL) was once one of the best-performing stocks around. The pandemic and a rise in online shopping helped drive superb growth, leading to monster gains in 2020.
But since this
2 Reasons to Buy Apple Stock, and 1 Reason to Sell
Shares in Apple (NASDAQ: AAPL) have risen 52% since Jan. 1 despite facing macroeconomic headwinds, reductions in consumer spending, and a 3% year-over-year revenue decline for fiscal 2023. The
Micron's Comeback Picks Up Steam. Is the Stock a Buy?
A brutal post-pandemic downturn in the memory-chip markets is finally coming to an end. Global shipments of PCs are expected to return to growth next year, and inventory levels across the PC supply
Forget Nvidia: Buy This Magnificent Artificial Intelligence (AI) Stock Instead
Excitement over artificial intelligence (AI) has created many millionaires this year, as chip stocks like Nvidia (NASDAQ: NVDA) have skyrocketed 230% since Jan. 1. The company has significantly
Forget Venmo: This Booming Segment Is Driving Growth for PayPal
PayPal (NASDAQ: PYPL) is unique in the fintech and payments space in that it has products and services that cater to different customer groups, including individuals, small businesses, and larger
2 Small-Cap Stocks Wall Street Left Behind, but That Could Explode in 2024
The benchmark S&P 500 index is sitting on a gain of 24% this year (including dividends), which is way above its average of 13.7% over the last 10 years.
But most of this year's gains were delivered
2 Artificial Intelligence (AI) Stocks That Could Go Parabolic
Artificial intelligence (AI) stocks have been in the limelight over the past year, thanks to the massive impact this technology is likely to have across multiple industries, with McKinsey estimating
2 Unstoppable Growth Stocks Down 10% and 65% to Buy Before They Soar in 2024
The biggest near-term threat to corporations might not be a recession or even climate change. According to research firm McKinsey & Company, cyberattacks are on track to cause $10.5 trillion in
This Semiconductor Stock Is the Next Artificial Intelligence (AI) Winner
In today's video, I discuss recent updates impacting Micron Technology (NASDAQ: MU). Check out the short video to learn more, consider subscribing, and click the special offer link below.
*Stock
7 Risks Intel Stock Investors Should Know for 2024
In today's video, I discuss recent updates impacting Intel (NASDAQ: INTC). Check out the short video to learn more, consider subscribing, and click the special offer link below.
*Stock prices used
2 "Magnificent Seven" Artificial Intelligence (AI) Stocks to Buy Hand Over Fist Before They Crush the Market in 2024
Technology stocks soared tremendously in 2023 following last year's dismal performance, evident from the impressive 65% jump in the Nasdaq-100 index this year. A group of seven megacap technology
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?
Investors looking for stocks that can make dramatic gains fairly quickly got what they wanted from CRISPR Therapeutics (NASDAQ: CRSP) this year. The stock is up more than 60% in 2023 after the
How AMD's Stock Price Can Continue to Grow in 2024
In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD). Check out the short video to learn more, consider subscribing, and click the special offer link below.
Are the "Magnificent Seven" Stocks Too Risky for You? Consider This Fund
Investing in the S&P 500 is normally a sound long-term strategy. But this year, while its valuation has been rising 23%, that has largely been due to seven stocks. Known as the "Magnificent Seven,"
6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy
December has been a big month for CRISPR Therapeutics (NASDAQ: CRSP). On Dec. 8, the Food and Drug Administration (FDA) granted approval for CRISPR's gene-editing therapy, Casgevy, as a treatment